hCAIX-IN-12 is an effective hCAIX inhibitor, IC50 for CAIX and CAII is 0.74 and 10.78 μM , respectively. hCAIX-IN-12 inhibits cell proliferation and induces apoptosis. HCAIX-IN-12 can increase the generation of ROS. HCAIX-IN-12 has research potential in colorectal cancer (CRC).

hCAIX-IN-12 (compound OX27) shows antiproliferative effect with IC 50 s of 6.0 μM for HCT-116 cells [1]. hCAIX-IN-12 decreases the expression of CAIX in HCT-116 cells and inhibits the expression of CAIX more pronouncedly in hypoxic conditions [1]. hCAIX-IN-12 (0-50 μM; 0-48 h) inhibits the colony formation in a dose-dependent manner and 7 inhibits the migration of HCT-116 cells [1]. hCAIX-IN-12 (6.0 μM; 48 h) induces apoptosis in HCT-116 cells [1]. hCAIX-IN-12 (6.0 μM; 24,48 h) increases in the levels of ROS in HCT-116 cells [1]. hCAIX-IN-12 causes depletion of HCT-116 cells in the G0/G1 (P2 65.21%) phase with an increase in the accumulation of cells in G2/M (P4 18.95%) phase [1]. hCAIX-IN-12 has high binding affinity for CAIX and substantial affinity for HSA [1].